Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1237714 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer.
Clin Transl Radiat Oncol
March 2025
Institute of Medical Science & Institute for Cancer Research, Keimyung University, Daegu, Republic of Korea.
Background: Combining radiotherapy (RT) with immune checkpoint inhibitors (ICIs) is a promising strategy that can enhance the therapeutic efficacy of ICIs. However, little is known about RT-induced changes in the expression of immune checkpoints, such as PD-L1, and their clinical implications in colorectal cancer (CRC). This study aimed to investigate the association between responsiveness to RT and changes in PD-L1 expression in human CRC tissue and cell lines.
View Article and Find Full Text PDFImmunotherapy in colorectal cancer: Statuses and strategies.
Heliyon
January 2025
Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Colorectal cancer (CRC) is widely recognized as the third most prevalent malignancy globally and the second leading cause of cancer-related mortality. Traditional treatment modalities for CRC, including surgery, chemotherapy, and radiotherapy, can be utilized either individually or in combination. However, these treatments frequently result in significant side effects due to their non-specificity and cytotoxicity affecting all cells.
View Article and Find Full Text PDFPartial intestinal obstruction caused by duodenal obstruction by the superior mesenteric artery and abdominal aorta in a middle-aged woman: A case report.
Heliyon
January 2025
Department of Colorectal and Stomach Cancer Surgery-1, Jilin Cancer Hospital, Changchun, Jilin Province, China.
A 55-year-old woman with non-small cell lung carcinoma complained of epigastric pain, bloating, anorexia and postprandial nausea and vomiting over a five-year period. An upper gastrointestinal pan-glucosamine contrast examination revealed a distinctive large, hook-shaped, ptotic gastric lumen with normal motility. The contrast agent demonstrated an abnormal round-trip flow anterior to the spine at the duodenal level, with pooling and gradual passage through this region in strands after prolonged retention.
View Article and Find Full Text PDFA non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent mutant colorectal cancer.
Heliyon
January 2025
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with -mutant colorectal cancer.
Methods: In the interval between completing CRT and pelvic exenteration, patients with resectable mutation-positive, locally advanced primary or current colorectal cancer, received 5-6 doses of TG02/GM-CSF.
Phloretin-nanospanlastics for targeting the Akt/PI3K signaling pathways in dimethylhydrazine-induced colon cancer in mice.
Int J Pharm X
June 2025
Technology of Radiology and Medical Imaging Department, Faculty of Applied Health Science Technology, October 6 University, Egypt.
Objectives: Colorectal cancer is the third most common cancer worldwide, accounting for approximately 10 % of all cancer cases. It is also the second leading cause of cancer-related deaths globally. Phloretin is a natural compound found in apples and other fruits.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!